Debevoise & Plimpton has secured an important victory for mining company Tethyan Copper Company Pty Limited (“TCC”), a joint venture between Antofagasta plc and Barrick Gold Corporation, winning an award of $4.087 billion in damages, plus $1.753 billion in pre-award interest, and $61.98 million in costs, against the Islamic Republic of Pakistan following the arbitration of claims before the International Centre for Settlement of Investment Disputes (“ICSID”). With a combined total of $5.9 billion, it is the second-largest ICSID award ever rendered. Read more > 

Debevoise & Plimpton LLP is advising One Rock Capital Partners in its acquisition of the Engineered Components & Systems (“EC&S”) segment of Actuant Corporation (NYSE: ATU). Read more >

Debevoise & Plimpton LLP is advising FWD Management Holdings, the Hong Kong registered business of FWD Group, in its acquisition of MetLife Limited and Metropolitan Life Insurance Company of Hong Kong Limited (collectively “MetLife Hong Kong) from MetLife Inc. (NYSE: MET). Read more >

Debevoise & Plimpton LLP has advised TPG in its definitive agreement to take over management of the existing assets of the Abraaj Group’s $1 billion Global Healthcare Fund. The fund will be named the Evercare Health Fund and will be managed by TPG Growth, the middle market and growth equity investment platform of TPG that also manages The Rise Fund, a global impact investing fund. Read more >

Debevoise & Plimpton LLP is advising J.P. Morgan Securities LLC (NYSE: JPM) as financial advisor to Allergan plc (NYSE: AGN), a pharmaceutical company, in connection with its sale to AbbVie Inc. (NYSE: ABBV). The sale consists of a cash and stock transaction for a transaction equity value of approximately $63 billion. The transaction represents a 45% premium to the closing price of Allergan's shares on June 24, 2019. Read more >